stockrowBiodesix, Inc. (BDSX) vs Myriad Genetics, Inc. (MYGN)
- Biodesix, Inc. BDSX 10.98 −44.66%
- Myriad Genetics, Inc. MYGN 6.06 −3.66%
Biodesix, Inc. and Myriad Genetics, Inc. are both Diagnostics & Research companies. Myriad Genetics, Inc. is the larger, with a market value of $601.6M against $209.3M — 2.9× the size. Biodesix, Inc. grew revenue faster over the last twelve months: 31.2% against −3.16%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −25.7%) and the higher return on invested capital (−19.9% vs −44.8%). Across the 18 metrics below, Myriad Genetics, Inc. leads on 12 and Biodesix, Inc. on 6.
Valuation
Profitability
| Metric | BDSX | MYGN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 0.00% | 68.83% | 48.32% |
| Operating margin | (18.69%) | (12.22%) | (5.68%) |
| Net margin | (25.74%) | (13.96%) | (4.10%) |
| Free cash flow margin | (18.30%) | (1.76%) | 0.00% |
| Return on equity | (778.89%) | (32.54%) | 0.00% |
| Return on assets | (29.65%) | (17.11%) | (6.05%) |
| Return on invested capital | (44.84%) | (19.92%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack